Kilitch Drugs Reports Quarterly Results for Q2 FY26; Standalone and Consolidated Performance Details
Kilitch Drugs (India) Limited released its Unaudited Financial Results for the quarter ending June 30, 2026. The company reported key financial metrics across both standalone and consolidated segments, detailing performance against previous periods.Standalone Financial Highlights
For the quarter ended June 30, 2026, Kilitch Drugs recorded a Total Income of 4,445.96 Lakhs. Net Sales from operations stood at 4,091.20 Lakhs, complemented by Other Income of 354.76 Lakhs.Total Expenses for the quarter amounted to 3,751.16 Lakhs, including Cost of Materials Consumed (2,024.54 Lakhs), Employee Benefit Expenses (352.50 Lakhs), and Other Expenses (749.66 Lakhs). The company generated a Profit before Exceptional items at 694.80 Lakhs.
The Net Profit after Tax from Continuing Operations for the quarter was reported at 505.24 Lakhs. Earnings per share (not annualised) were recorded at 1.45 for both Basic and Diluted calculations.
The standalone financial performance data is presented in the table below:
| Metric | Qtr Ended June 30, 2026 (Unaudited) | Qtr Ended March 31, 2026 (Audited) | Qtr Ended June 30, 2025 (Unaudited) | Year Ended March 31, 2026 (Audited) |
|---|---|---|---|---|
| Net Sales/Income from operations | 4,091.20 | 7,196.88 | 3,412.20 | 18,857.43 |
| Total Income | 4,445.96 | 7,310.51 | 3,761.72 | 20,242.28 |
| Total Expenses | 3,751.16 | 5,377.83 | 3,163.55 | 16,086.91 |
| Net Profit after Tax from Continuing Operations | 505.24 | 1,399.90 | 479.41 | 3,239.96 |
| EPS (Basic/Diluted) | 1.45 | 4.08 | 1.49 | 9.57 |
Consolidated Financial Performance
The consolidated results for the quarter ending June 30, 2026, showed a Total Income of 4,777.58 Lakhs. Net Sales/Income from Operations stood at 4,487.89 Lakhs, and Other Income was 289.69 Lakhs.Consolidated expenses amounted to 4,391.29 Lakhs. The company recorded a Profit before Exceptional items of 386.29 Lakhs for the period. After accounting for taxes, the Net Profit from continuing operations stood at 196.74 Lakhs. Earnings per share (not annualised) were reported as 0.83 for both Basic and Diluted metrics.
The key consolidated financial data is summarized in the table below:
| Metric | Qtr Ended June 30, 2026 (Unaudited) | Qtr Ended March 31, 2026 (Audited) | Qtr Ended June 30, 2025 (Unaudited) | Year Ended March 31, 2026 (Audited) |
|---|---|---|---|---|
| Net Sales/Income from Operations | 4,487.89 | 8,960.27 | 9,431.98 | 23,547.49 |
| Total Income | 4,777.58 | 9,009.54 | 4,569.72 | 24,671.35 |
| Total Expenses | 4,391.29 | 6,988.49 | 4,224.82 | 20,805.91 |
| Profit before Exceptional items | 386.29 | 2,021.05 | 344.90 | 3,865.44 |
| Net Profit after Tax from continuing operations | 196.74 | 1,488.28 | 226.25 | 2,950.03 |
| EPS (Basic/Diluted) | 0.83 | 4.24 | 0.94 | 8.91 |
KILITCH Stock Price Movement
Shares of Kilitch Drugs (India) Limited slipped by 0.35% on Thursday, settling at ₹191.22 following a decline of ₹0.67 from the previous close. The equity was traded with a volume of 17,758 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.